Your browser doesn't support javascript.
loading
Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.
Kwon, Jason J; Hajian, Behnoush; Bian, Yuemin; Young, Lucy C; Amor, Alvaro J; Fuller, James R; Fraley, Cara V; Sykes, Abbey M; So, Jonathan; Pan, Joshua; Baker, Laura; Lee, Sun Joo; Wheeler, Douglas B; Mayhew, David L; Persky, Nicole S; Yang, Xiaoping; Root, David E; Barsotti, Anthony M; Stamford, Andrew W; Perry, Charles K; Burgin, Alex; McCormick, Frank; Lemke, Christopher T; Hahn, William C; Aguirre, Andrew J.
Afiliação
  • Kwon JJ; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Hajian B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Bian Y; Harvard Medical School, Boston, Massachusetts, USA.
  • Young LC; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Amor AJ; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Fuller JR; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Fraley CV; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Sykes AM; Helix Biostructures, Indianapolis, IN, USA.
  • So J; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Pan J; Harvard Medical School, Boston, Massachusetts, USA.
  • Baker L; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Lee SJ; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Wheeler DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mayhew DL; Harvard Medical School, Boston, Massachusetts, USA.
  • Persky NS; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Yang X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Root DE; Harvard Medical School, Boston, Massachusetts, USA.
  • Barsotti AM; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Stamford AW; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Perry CK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Burgin A; Harvard Medical School, Boston, Massachusetts, USA.
  • McCormick F; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Lemke CT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hahn WC; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nature ; 609(7926): 408-415, 2022 09.
Article em En | MEDLINE | ID: mdl-35831509
Receptor tyrosine kinase (RTK)-RAS signalling through the downstream mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and survival. The SHOC2-MRAS-PP1C holophosphatase complex functions as a key regulator of RTK-RAS signalling by removing an inhibitory phosphorylation event on the RAF family of proteins to potentiate MAPK signalling1. SHOC2 forms a ternary complex with MRAS and PP1C, and human germline gain-of-function mutations in this complex result in congenital RASopathy syndromes2-5. However, the structure and assembly of this complex are poorly understood. Here we use cryo-electron microscopy to resolve the structure of the SHOC2-MRAS-PP1C complex. We define the biophysical principles of holoenzyme interactions, elucidate the assembly order of the complex, and systematically interrogate the functional consequence of nearly all of the possible missense variants of SHOC2 through deep mutational scanning. We show that SHOC2 binds PP1C and MRAS through the concave surface of the leucine-rich repeat region and further engages PP1C through the N-terminal disordered region that contains a cryptic RVXF motif. Complex formation is initially mediated by interactions between SHOC2 and PP1C and is stabilized by the binding of GTP-loaded MRAS. These observations explain how mutant versions of SHOC2 in RASopathies and cancer stabilize the interactions of complex members to enhance holophosphatase activity. Together, this integrative structure-function model comprehensively defines key binding interactions within the SHOC2-MRAS-PP1C holophosphatase complex and will inform therapeutic development .
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas ras / Microscopia Crioeletrônica / Complexos Multiproteicos / Peptídeos e Proteínas de Sinalização Intracelular / Proteína Fosfatase 1 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas ras / Microscopia Crioeletrônica / Complexos Multiproteicos / Peptídeos e Proteínas de Sinalização Intracelular / Proteína Fosfatase 1 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article